Twenty-one 2-(N-arylsulfonylindol-3-yl)-3-aryl-1,3-thiazolidin-4-ones (4a-u) were synthesized and evaluated
as HIV-1 inhibitors in vitro. Among all compounds, compounds 4n and 4p displayed the potent anti-HIV-1 activities with
EC50 values of 3.48 and 8.61 μg/mL, and TI values of 34.08 and 23.22, respectively. It demonstrated that, to a series of
2-(N-arylsulfonyl-6-methylindol-3-yl)-3-aryl-1,3-thiazolidin-4-one derivatives, introduction of R2 as 4-Cl and R3 as H or
3-Cl could afford the more promising and potent compounds.
合成了21个2-(N-芳基磺酰基
吲哚-3-基)-3-芳基-1,3-
噻唑烷-4-酮(4a-u),并对其进行了体外抗HIV-1活性评价。在所有化合物中,化合物4n和4p表现出了较强的抗HIV-1活性,其
EC50值分别为3.48和8.61 μg/mL,治疗指数(TI)分别为34.08和23.22。研究表明,在一系列的2-(N-芳基磺酰基-
6-甲基吲哚-3-基)-3-芳基-1,3-
噻唑烷-4-酮衍
生物中,引入R2为4-
氯,R3为氢或3-
氯可获得更具潜力的强效化合物。